Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.47 |
| ▸ | HTR2B | P41595 | 3/20 | 0.47 |
| ▸ | PNMT | P11086 | 3/20 | 0.47 |
| ▸ | HTR2A | P28223 | 2/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.38 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3600557 | 0.82 | PNMT (0.49) | HTR2CHTR2BPNMTHTR2AADRA2A | |
| SCHEMBL3606170 | 0.79 | HTR2A (0.50) | HTR2CHTR2BPNMTHTR2AADRA2A | |
| SCHEMBL3602160 | 0.79 | PNMT (0.49) | HTR2CHTR2BPNMTHTR2AADRA2A | |
| SCHEMBL8730062 | 0.78 | TDP1 (0.45) | HTR2CHTR2BHTR2AKDM4EPOLB | |
| SCHEMBL829320 | 0.76 | HTR2C (0.53) | HTR2CHTR2BPNMTHTR2AKDM4E | |
| SCHEMBL12682948 | 0.76 | HTR2C (0.53) | HTR2CHTR2BPNMTHTR2ACD274 | |
| SCHEMBL2062200 | 0.76 | KDM4E (0.43) | HTR2CHTR2BHTR2AKDM4EPOLB | |
| Hydrochloric Acid SCHEMBL16039618 | 0.75 | HTR2C (0.51) | HTR2CHTR2BPNMTHTR2AKDM4E | |
| SCHEMBL17583866 | 0.75 | HTR2C (0.51) | HTR2CHTR2BPNMTHTR2ACD274 | |
| SCHEMBL3776258 | 0.75 | HTR2C (0.79) | HTR2CHTR2BPNMTHTR2AADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298285-A1 | Biclycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof | RENOVIS, INC. | 2010-11-25 | — | — | US | disclosed |
| US-20100298285-A1 | Biclycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof | RENOVIS, INC. | 2010-11-25 | — | — | US | disclosed |
| WO-2007109182-A2 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | RENOVIS, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298285-A1 | Biclycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX1 | HTR2C 1168/4885HTR2B 1096/4885PNMT 4045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.